Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Basil S Lewis

Showing results (221-230 of 240) with videos related to

Pageof 24
Sort By:
The New England Journal of Medicine|February 12, 2011
Apixaban in patients with atrial fibrillationStuart J Connolly, John Eikelboom, Campbell Joyner, et al.
The New England Journal of Medicine|April 5, 2016
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseEva M Lonn, Jackie Bosch, Patricio López-Jaramillo, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
The New England Journal of Medicine|August 30, 2011
Apixaban versus warfarin in patients with atrial fibrillationChristopher B Granger, John H Alexander, John J V McMurray, et al.
JACC. Advances|April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsSem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trialSonia S Anand, Jackie Bosch, John W Eikelboom, et al.
European Journal of Heart Failure|November 10, 2025
Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular PharmacotherapyGianluigi Savarese, Felix Lindberg, Antonio Cannata, et al.
European Heart Journal|June 3, 2021
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF studyEwa A Jankowska, Bridget-Anne Kirwan, Mikhail Kosiborod, et al.
Lancet (London, England)|November 16, 2020
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trialPiotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, et al.
European Heart Journal|June 10, 2021
Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategyFilippo Crea, Holger Thiele, Dirk Sibbing, et al.
Pageof 24

Showing results (221-230 of 240) with videos related to

Sort By:
Pageof 24
The New England Journal of Medicine|February 12, 2011
Apixaban in patients with atrial fibrillationStuart J Connolly, John Eikelboom, Campbell Joyner, et al.
The New England Journal of Medicine|April 5, 2016
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseEva M Lonn, Jackie Bosch, Patricio López-Jaramillo, et al.
Circulation|September 27, 2019
Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS TrialStephan Windecker, Renato D Lopes, Tyler Massaro, et al.
The New England Journal of Medicine|August 30, 2011
Apixaban versus warfarin in patients with atrial fibrillationChristopher B Granger, John H Alexander, John J V McMurray, et al.
JACC. Advances|April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsSem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
Lancet (London, England)|November 15, 2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trialSonia S Anand, Jackie Bosch, John W Eikelboom, et al.
European Journal of Heart Failure|November 10, 2025
Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular PharmacotherapyGianluigi Savarese, Felix Lindberg, Antonio Cannata, et al.
European Heart Journal|June 3, 2021
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF studyEwa A Jankowska, Bridget-Anne Kirwan, Mikhail Kosiborod, et al.
Lancet (London, England)|November 16, 2020
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trialPiotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, et al.
European Heart Journal|June 10, 2021
Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategyFilippo Crea, Holger Thiele, Dirk Sibbing, et al.
Pageof 24